Jaqueline Marquez

Jaqueline Marquez

Auto-generated profile, based on publicly available information

Jaqueline Marquez

University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, California

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 March 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ACAtish Choudhury
Atish Choudhury
LKLucia Kwak
Lucia Kwak
ACAlexander Cheung
Alexander Cheung
KAKathryn M. Allaire
Kathryn M. Allaire
JMJaqueline Marquez
Jaqueline Marquez
LFLawrence Fong
Lawrence Fong
The checkpoint immunotherapeutic pembrolizumab induces responses in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Radium-223 (R223) may increase immunogenicity of bone metastases and increase pembrolizumab (P) activity. In a randomized phase II study, we assessed the effect of R223+P compared with R223 on tumor immune infiltration, safety, and clinical outcomes in patients with mCRPC. The primary endpoint was differences in CD4+ and CD8+ T-cell infiltrate in 8-week versus baseline bone metastasis biopsies; secondary endpoints were safety, radiographic progression-free survival (rPFS), and overall survival (OS). Of the 42 treated patients (29 R223+P, 13 R223), 18 R223+P and 8 R223 patients had evaluable paired tumor biopsies. Median fold-change of CD4+ T cells was −0.7 (range: −9.3 to 4.7) with R223+P and 0.1 (−11.1 to 3.7) with R223 (P = 0.66); for CD8+ T cells, median fold-change was −0.6 (−7.4 to 5.3) with R223+P and −1.3 (−3.1 to 4.8) with R223 (P = 0.66). Median rPFS and OS was 6.1 (95% confidence interval: 2.7–11.0) and 16.9 months [12.7–not reached (NR)], respectively, with R223+P and 5.7 (2.6–NR) and 16.0 (9.0–NR), respectively, with R223. Although R223+P was well tolerated with no unexpected toxicity, the combination did not improve efficacy. High-dimensional flow cytometry demonstrated minimal immune modulation with R223, whereas R223+P induced CTLA-4 expression on circulating CD4+ T cells. Clinical responders possessed lower circulating frequencies of Ki67+ T and myeloid cells at baseline and higher circulating frequencies of TIM-3+ T and myeloid cells by week 9. Although R223+P did not induce T-cell infiltration into the tumor microenvironment, exhaustion of induced peripheral T-cell immune responses may dampen the combination's clinical activity.

26 January 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints. See related Spotlight by Nasrollahi and Davar, p. 383.

2 April 2024
Verified
Other
Open access
HCHewitt Chang
Hewitt Chang
JMJaqueline Marquez
Jaqueline Marquez
BCBrandon K. Chen
Brandon K. Chen
DKDaniel M. Kim
Daniel M. Kim
MCMichael L. Cheng
Michael L. Cheng
LFLawrence Fong
Lawrence Fong
Denosumab is a fully human mAb that binds receptor activator of NFκB ligand (RANKL). It is routinely administered to patients with cancer to reduce the incidence of new bone metastasis. RANK–RANKL interactions regulate bone turnover by controlling osteoclast recruitment, development, and activity. However, these interactions also can regulate immune cells including dendritic cells and medullary thymic epithelial cells. Inhibition of the latter results in reduced thymic negative selection of T cells and could enhance the generation of tumor-specific T cells. We examined whether administering denosumab could modify modulate circulating immune cells in patients with cancer. Blood was collected from 23 patients with prostate cancer and 3 patients with renal cell carcinoma, all of whom had advanced disease and were receiving denosumab, prior to and during denosumab treatment. Using high-dimensional mass cytometry, we found that denosumab treatment by itself induced modest effects on circulating immune cell frequency and activation. We also found minimal changes in the circulating T-cell repertoire and the frequency of new thymic emigrants with denosumab treatment. However, when we stratified patients by whether they were receiving chemotherapy and/or steroids, patients receiving these concomitant treatments showed significantly greater immune modulation, including an increase in the frequency of natural killer cells early and classical monocytes later. We also saw broad induction of CTLA-4 and TIM3 expression in circulating lymphocytes and some monocyte populations. These findings suggest that denosumab treatment by itself has modest immunomodulatory effects, but when combined with conventional cancer treatments, can lead to the induction of immunologic checkpoints.See related Spotlight by Nasrollahi and Davar, p. 383.

17 June 2026
Verified
Other
Open access
ACAtish Choudhury
Atish Choudhury
LKLucia Kwak
Lucia Kwak
ACAlexander Cheung
Alexander Cheung
KAKathryn M. Allaire
Kathryn M. Allaire
JMJaqueline Marquez
Jaqueline Marquez
LFLawrence Fong
Lawrence Fong
Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. baseline CD4+FoxP3- (effector) proportion above (high) vs. below (low) median. B. baseline CD8+ proportion above vs. below median. C. baseline CD8+ / CD4+FoxP3+ (Treg) ratio above vs. below median. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.

17 June 2026
Verified
Other
Open access
ACAtish Choudhury
Atish Choudhury
LKLucia Kwak
Lucia Kwak
ACAlexander Cheung
Alexander Cheung
KAKathryn M. Allaire
Kathryn M. Allaire
JMJaqueline Marquez
Jaqueline Marquez
LFLawrence Fong
Lawrence Fong
Kaplan-Meier estimates of time to treatment failure (TTF), radiographic progression-free survival (rPFS), and overall survival (OS) by A. CD4+FoxP3- (effector) proportion increase vs. decrease from baseline to 8-week biopsy. B. CD8+ increase vs. decrease. C. CD8+ / CD4+FoxP3+ (Treg) ratio increase vs. decrease. N.B. Patients were event-free for 2 months as they need to have on treatment biopsy at week 8 of treatment.

17 June 2026
Verified
Other
Open access
ACAtish Choudhury
Atish Choudhury
LKLucia Kwak
Lucia Kwak
ACAlexander Cheung
Alexander Cheung
KAKathryn M. Allaire
Kathryn M. Allaire
JMJaqueline Marquez
Jaqueline Marquez
LFLawrence Fong
Lawrence Fong
Proportion of patients who experienced any or given category of symptomatic skeletal events by the treatment arms